Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 2, 2013, Pages

  Galaal, Khadra ^a   van der Heijden, Esther ^b   Godfrey, Keith ^c   Naik, Raj ^c   Kucukmetin, Ali ^c   Bryant, Andrew ^d   Das, Nagindra ^a   Lopes, Alberto D ^a  

^a ROYAL CORNWALL HOSPITAL   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IFOSFAMIDE; ALKYLATING AGENT; PACLITAXEL;

ADJUVANT CHEMORADIOTHERAPY; ALOPECIA; ANEMIA; ANOREXIA; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOSARCOMA; CARDIOVASCULAR DISEASE; CLINICAL ASSESSMENT; DIARRHEA; FEMALE; FUNCTIONAL STATUS; GASTROINTESTINAL SYMPTOM; HEMATOLOGIC DISEASE; HUMAN; INTERMETHOD COMPARISON; LEUKOPENIA; LIVER DISEASE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; PROCTITIS; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SKIN ALLERGY; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THERAPY EFFECT; THROMBOCYTOPENIA; UROGENITAL TRACT DISEASE; UTERINE CARCINOSARCOMA; UTERUS CANCER; WHOLE BODY RADIATION; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; META ANALYSIS; METHODOLOGY; MORTALITY; RADIOTHERAPY;

ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOSARCOMA; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; IFOSFAMIDE; PACLITAXEL; RADIOTHERAPY; RADIOTHERAPY, ADJUVANT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UTERINE NEOPLASMS;

EID: 84875512839     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006812.pub3     Document Type: Review

References (46)

1. Homesley HD, Filiaci V, Markman M, Bitterman P, Eaton L, Kilgore LC, et al.Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. Journal of Clinical Oncology Feb 10 2007;25(5):526-31.
2. Sutton G, Brunetto VL, Kilgore L, Soper JT, McGehee R, Olt G, et al.A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecologic Oncology 2000;79(2):147-53.
3. Wolfson AH, Brady MF, Rocereto T, Mannel RS, Lee YC, Futoran RJ, et al.A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecologic Oncology 2007;107(2):177-85.
4. Asbury R, Blessing JA, Podczaski E, Ball H. A phase II trial of amonafide in patients with mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. American Journal of Clinical Oncology 1998;21(3):306-7.
5. Currie JL, Blessing JA, McGehee R, Soper JT, Berman M. Phase II trial of hydroxyurea, dacarbazine (DTIC), and etoposide (VP-16) in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. Gynecologic Oncology 1996;61(1):94-6.
6. Curtin JP, Blessing JA, Soper JT, DeGeest K. Paclitaxel in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecologic Oncology 2001;83(2):268-70.
7. Fowler JM, Blessing JA, Burger RA, Malfetano JH. Phase II evaluation of oral trimetrexate in mixed mesodermal tumors of the uterus: a Gynecologic Oncology Group study. Gynecologic Oncology 2002;85(2):311-4.
8. Miller DS, Blessing JA, Schilder J, Munkarah A, Lee YC. Phase II evaluation of topotecan in carcinosarcoma of the uterus: A Gynecologic Oncology Group study. Gynecologic Oncology 2005;98(2):217-21.
9. Perez CA, Askin F, Balgan RJ, Kao MS, Kraus FT, Perez BM, et al.Effects of irradiation on mixed mullian tumors of the uterus. Cancer 1979;43(4):1274-84.
10. Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, DeGeest K, et al.A phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a GynecologicOncology Group Study. Journal of Clinical Oncolcogy 2010;28(16):2727-31.
11. Ramondetta LM, Burke TW, Jhingran A, Schmandt R, Bevers MW, Wolf JK, et al.A phase II trial of cisplatin, ifosfamide, and mesna in patients with advanced or recurrent uterine malignant mixed mullerian tumors with evaluation of potential molecular targets.[see comment]. Gynecologic Oncology 2003 Sep;90(3):529-36.
12. Resnik E, Chambers SK, Carcangiu ML, Kohorn EI, Schwartz PE, Chambers JT. A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed müllerian tumors (MMT) of the uterus. Gynecologic Oncology 1995;56(3):370-5.
13. Sutton GP, Blessing JA, Rosenshein N, Photopulos G, DiSaia PJ. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). American Journal of Obstetrics and Gynecology 1989;161(2):309-12.
14. Sutton G, Kauderer J, Carsonc LF, Lentz SS, Whitney CW, Gallion H. Adjuvant ifosfamide and cisplatin in patients with completely resectedstage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus:a Gynecologic Oncology Group study. Gynecologic Oncology 2005;96(3):630-4.
15. Toyoshima M, Akahira JI, Matsunaga G, Niikura H, Ito K, Yaegashi N, et al.Clinical experience with combination paclitaxel and carboplatin therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecologic Oncology 2004;94(3):774-8.
16. Arrastia CD, Fruchter RG, Clark M, Maiman M, Remy JC, Macasaet M, et al.Uterine carcinosarcomas: Incidence and trends in management and survival. Gynecologic Oncology 1997;65(1):158-63.
17. Barwick KW, LiVolsi VA. Malignant mixed mullerian tumors of the uterus. A clinicopathologic assessment of 34 cases. American Journal of Surgical Pathology 1979;3(2):125-35.
18. Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989-1999. Gynecologic Oncology 2004;93(1):204-8.
19. Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. Journal of Clinical Epidemiology 1997;50(6):683-91.
20. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ. Malignant mixed mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. International Journal of Radiation Oncology Biology Physics 2004;58(3):786-96.
21. Chi DS, Mychalczak B, Saigo PE, Rescigno J, Brown CL. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. [Review] [21 refs]. Gynecologic Oncology 1997 Jun;65(3):493-8.
22. CTCAE. Common Terminology Criteria for Adverse Events. (http://ctep.cancer.gov/forms/CTCAEv3.pdf) 9th August 2006; Vol. v3.0 (CTCAE).
23. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care: Meta-Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177-88.
25. El-Nashar SA, Mariani A. Uterine carcinosarcoma. Clinical Obstetetrics and Gynecology 2011 Jun;54(2):292-304.
26. FIGO Committee on Gynecologic Oncology. Revised FIGO staging for carcinoma of vulva, cervix, and endometrium. International Journal of Gynecology and Obstetrics 2009;105(2):103-4.
27. Gadducci A, Sartori E, Landoni F, Zola P, Maggino T, Cosio S, et al.The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases. European Journal of Gynaecological Oncology 2002;23(4):295-9.
28. Galaal K, Kew FM, Tam KF, Lopes AD, Meirovitz M, Naik R, et al.Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma. European Journal of Obstetrics, Gynecology and Reproductive Bbiology 2009;143(2):88-92.
29. Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. Journal of the National Cancer Institute 1986;76(3):339-402.
30. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
31. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1. The Cochrane Collaboration 2011. Available from www.cochrane-handbook.org, [updated March 2011].
32. Le T. Adjuvant pelvic radiotherapy for uterine carcinosarcoma in a high risk population. European Journal of Surgical Oncology 2001;27(3):282-5.
33. Major FJ, Blessing JA, Silverberg SG, Morrow CP, Creasman WT, Currie JL, et al.Prognostic factors in early-stage uterine sarcoma. A Gynaecologic Oncology Group study. Cancer 1993;7(Suppl 4):1702-9.
34. McCluggage WG. Uterine carcinosarcomas (malignant mixed mullerian tumours) are metaplastic carcinomas. International Journal of Gynecological Cancer 2002;12(6):687-90.
35. Menczer J, Levy T, Piura B, Chetrit A, Altaras M, Meirovitz M, et al.A comparison between different postoperative treatment modalities of uterine carcinosarcoma. Gynecologic Oncology 2005;97(1):166-70.
36. Olah KS, Dunn JA, Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: results of a retrospective study of 423 cases of uterine sarcoma. British Journal of Obstetrics and Gynaecology 1992;99:590-4.
37. Omura GA, Blessing JA, Major F, Silverberg S. A. randomised trial of adriamycin versus no adjuvant chemotherapy in stage I and stage II uterine sarcomas. Proceedings of the American Society of Clinical Oncology. 1983; Vol. C-580:149.
38. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17:2815-34.
39. Sartori E, Bazzurini L, Gadducci A, Landoni F, Lissoni A, Maggino T, et al.Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecologic Oncology 1997;67(1):70-5.
40. Spanos WJ Jr, Peters LJ, Oswald MJ. Patterns of recurrence in malignant mixed mullerian tumor of the uterus. Cancer 1986;57(1):155-9.
41. Szukala SA, Marks JR, Burchette JL, Elbendary AA, Krigman HR. Co-expression of p53 by epithelial and stromal elements in carcinosarcomaof the female genital tract: an immunohistochemical study of19 cases. International Journal of Gynecological Cancer 1999;9(2):131-6.
42. Thigpen JT, Blessing JA, DeGeest K, Look KY, Homesley HD. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: A Gynecologic Oncology Group study. Gynecologic Oncology 2004;93(2):336-9.
43. Van Rijswijk REN, Tognon G, Burger CW, Baak JP, Kenemans P, Vermorken JB. The effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract. International Journal of Gynecological Cancer 1994;4(1):52-60.
44. Young JL, Percy CL, Asire AJ, Berg JW, Cusano MM, Gloeckler LA, et al.Cancer incidence and mortality in the United States, 1973-77. National Cancer Institute Monograph 1981;57:1-187.
45. Zelmanowicz A, Hildesheim A, Sherman ME, Sturgeon SR, Kurman RJ, Barrett RJ, et al.Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecologic Oncology 1998;69( 3):253-7.
46. Galaal K, Godfrey K, Naik R, Kucukmetin A, Bryant A. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD006812.pub2]